Immune Competitors

IMUN -  USA Stock  

USD 3.12  0.22  7.59%

Immune Therapeutics competes with Wuxi Biologics, Wuxi Biologics, Ginkgo Bioworks, Csl, and Biontech; as well as few others. The company conducts business under Healthcare sector and is part of Biotechnology industry. Analyzing Immune Therapeutics competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Immune Therapeutics to its intrinsic valuation because they are able to contrast its competitors on a relative basis.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Immune Therapeutics competition on your existing holdings. Please see Immune Therapeutics Correlation with its peers.

Immune Competition 

 
Refresh

Specify up to 10 symbols:

Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of Immune Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of Immune Therapeutics in the context of predictive analytics.
Hype
Prediction
LowEstimated ValueHigh
0.153.0715.16
Details
Intrinsic
Valuation
LowReal ValueHigh
0.122.5014.59
Details
Naive
Forecast
LowNext ValueHigh
0.073.4015.49
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
2.213.124.03
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Immune Therapeutics. Your research has to be compared to or analyzed against Immune Therapeutics' peers to derive any actionable benefits. When done correctly, Immune Therapeutics' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in Immune Therapeutics.

Immune Therapeutics Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Immune Therapeutics and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Immune and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Immune Therapeutics does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio

Immune Therapeutics Competition Risk-Adjusted Indicators

Nowadays, there is a big difference between Immune Therapeutics stock performing well and Immune Therapeutics company doing well compared to the competition. There are way too many exceptions to the normal that investors can tell for sure what's good or bad unless they analyze Immune Therapeutics' multiple risk-adjusted performance indicators. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean
Deviation
Jensen
Alpha
Sortino
Ratio
Treynor
Ratio
Semi
Deviation
Information
Ratio
Expected
Shortfall
Potential
Upside
Value
At Risk
Maximum
Drawdown
WUX
 2.89 (0.13)  0.00  0.91  0.00 (0.0449)  0.00  5.32 (5.53)  21.90 
WUX
 2.87 (0.21)  0.00 (2.10)  0.00 (0.05)  0.00  9.85 (7.94)  20.84 
DNA
 3.13  0.54  0.13  0.33  3.22  0.11 (4.03)  12.73 (7.93)  24.34 
CSL
 1.21  0.10  0.05  0.33  1.35  0.05 (1.34)  2.45 (1.98)  6.63 
BNTX
 4.13  0.30  0.05 (1.07)  5.24  0.0439 (4.31)  10.37 (8.84)  31.56 
Csl
 1.29  0.03  0.01  0.09  1.85  0.0095 (1.59)  2.73 (2.78)  11.83 
MRNA
 3.76  0.27  0.04 (0.38)  4.93  0.0393 (3.89)  7.84 (6.60)  32.74 
REGN
 1.14 (0.07)  0.00 (0.22)  0.00 (0.07)  0.00  2.76 (2.69)  9.39 

Immune Therapeutics Competitive Analysis

The better you understand Immune Therapeutics competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Immune Therapeutics' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Immune Therapeutics' competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
IMUN
WUX
WUX
DNA
CSL
BNTX
Csl
MRNA
REGN
 7.59 
 3.12 
Immune
 1.40 
 29.65 
WXXWY
 9.60 
 13.47 
WXIBF
 10.53 
 12.32 
Ginkgo
 2.88 
 109.10 
Csl
 3.09 
 261.09 
Biontech
 0.55 
 217.50 
Csl
 0.55 
 334.84 
Moderna
 3.42 
 543.48 
Regeneron
Market Volatility
(90 Days Market Risk)
Market Performance
(90 Days Stock Performance)
Odds of Financial Distress
(Probability Of Bankruptcy)
Current Valuation
(Equity Enterprise Value)
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Number of Shares Shorted
Shares Owned by Insiders
Current Ratio
Profit Margin
EBITDA
Current Valuation
Cash Flow from Operations
Operating Margin
Retained Earnings
Current Asset
Five Year Return
Beta
Price to Book
Shares Outstanding
Total Debt
Return On Equity
Price to Earning
Z Score
Shares Owned by Institutions
Book Value Per Share
Return On Asset
Cash and Equivalents
Current Liabilities
Price to Earnings To Growth
Total Asset
Last Dividend Paid
Short Ratio
Price to Sales
Market Capitalization
Cash per Share
Net Income
Earnings Per Share
Debt to Equity
Revenue
Working Capital
Gross Profit
Coefficient Of Variation
Mean Deviation
Jensen Alpha
Total Risk Alpha
Sortino Ratio
Downside Variance
Standard Deviation
Kurtosis
Potential Upside
Treynor Ratio
Maximum Drawdown
Variance
Market Risk Adjusted Performance
Risk Adjusted Performance
Skewness
Semi Deviation
Information Ratio
Value At Risk
Expected Short fall
Downside Deviation
Semi Variance

Immune Therapeutics Competition Performance Charts

Complement your Immune Therapeutics position

In addition to having Immune Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Marijuana Thematic Idea Now

Marijuana
Marijuana Theme
Small and mid-cap equities that are involved in production and delivery of Marijuana products. This theme is designed for investors that are willing to accept higher levels of market risk inherited by Marijuana production in the United States. Marijuana theme has 36 constituents.
View All  Next Launch Marijuana
Please see Immune Therapeutics Correlation with its peers. Note that the Immune Therapeutics information on this page should be used as a complementary analysis to other Immune Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.

Complementary Tools for Immune OTC Stock analysis

When running Immune Therapeutics price analysis, check to measure Immune Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immune Therapeutics is operating at the current time. Most of Immune Therapeutics' value examination focuses on studying past and present price action to predict the probability of Immune Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Immune Therapeutics' price. Additionally, you may evaluate how the addition of Immune Therapeutics to your portfolios can decrease your overall portfolio volatility.
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Go
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Go
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Go
CEO Directory
Screen CEOs from public companies around the world
Go
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Go
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Go
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Go
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Go
Bond Directory
Find actively traded corporate debentures issued by US companies
Go
The market value of Immune Therapeutics is measured differently than its book value, which is the value of Immune that is recorded on the company's balance sheet. Investors also form their own opinion of Immune Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Immune Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immune Therapeutics' market value can be influenced by many factors that don't directly affect Immune Therapeutics underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immune Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine Immune Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immune Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.